Economic information and modeling reportBudget impact modelResults
Scenario analyses
6 evidence topics · 8 sources
Budget impact model of cretostimogene grenadenorepvec: scenario analyses
No evidence found.
Scenario and sensitivity analyses recommended for budget impact analysis
Scenario and sensitivity analyses of a published budget impact model
Sensitivity analyses of a published cost-effectiveness model
“Gemcitabine/docetaxel lost cost effectiveness compared to RC if the one-year recurrence free survival decreased from 60% to 50.4%, if the one-year progression free survival decreased from 97% to 92.2%, if the upstaging rate with delayed RC was greater than or equal to 36%, or if the three-month gemcitabine/docetaxel costs exceeded $8,808.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One-way sensitivity analysis showed the model was sensitive to cost alone. Nadofaragene became cost effective with a 21% reduction in 3-month cost, while NAI-BCG would require a 67% cost reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a probabilistic sensitivity analysis with all model parameters varied simultaneously, the most cost-effective strategy remained pembrolizumab (54%), followed by nadofaragene (35%), and NAI-BCG (11%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Scenario and sensitivity analyses of a published cost-per-responder model
Scenario analyses in the ICER review
“In scenario analyses, when the CR of the hypothetical comparator was increased to 20% in the CIS ± Ta/T1 population, the incremental cost-effectiveness ratio for nadofaragene firadenovec and oportuzumab monatox increased to $155,000 and $407,000, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The model’s base-case assumption of an ineffective (0% CR) hypothetical comparator is likely overly conservative, so the base-case results can be viewed as the most optimistic scenario and should therefore be interpreted with caution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote